Close menu




March 24th, 2025 | 07:20 CET

Bayer, Vidac Pharma, BioNTech – Setbacks and New Standards

  • Biotechnology
  • Biotech
  • Pharma
Photo credits: pixabay.com

Glyphosate and no end in sight. Bayer's 2018 acquisition of US agricultural company Monsanto continues to develop into a billion-dollar grave, with a court again ruling against the Leverkusen-based company. Billions in revenue also disappeared from the books of vaccine manufacturer BioNTech after the COVID-19 pandemic subsided. In contrast, an innovative biopharmaceutical company is setting new standards in treating pediatric brain tumors.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: BAYER AG NA O.N. | DE000BAY0017 , VIDAC PHARMA HOLDING PLC | GB00BM9XQ619 , BIONTECH SE SPON. ADRS 1 | US09075V1026

Table of contents:


    Bayer – Now it is getting serious

    News published over the weekend is usually negative in nature. This was also the case with the latest bad news from pharmaceutical and agricultural giant Bayer. It concerns the dominant topic of the last few years that has gotten the Leverkusen-based company into serious trouble - lawsuits for damages related to the weed killer glyphosate.

    A jury in the US state of Georgia ordered the Bayer Group to pay around USD 2.1 billion to a plaintiff who sued, claiming to have developed cancer as a result of Roundup. The ordered payment is one of the highest amounts imposed so far in the entire litigation. To date, Bayer has paid around USD 10 billion in legal disputes related to glyphosate. However, 60,000 cases are still open and have yet to be heard. In this context, Bayer recently announced that it would obtain a risk buffer of EUR 2.5 billion to settle the legal disputes.

    On Saturday, Bayer rejected the recent court ruling as unfounded. The Company emphasized that the decision is not in line with the vast majority of scientific research. "We are confident that we have strong arguments on appeal to overturn this ruling or at least reduce the excessive and unconstitutional damages," the Company said in a statement.

    Vidac Pharma – A milestone for breakthrough therapies

    In contrast to the Bayer Group, the biopharmaceutical company, led by Max Herzberg, one of the founding fathers of the Israeli life sciences industry, is doing extremely well. The Company's approach is revolutionary. Vidac Pharma is developing anti-cancer drugs by altering the tumor's hyperglycolytic microenvironment and targeting the overexpression and mis-anchoring of the metabolic checkpoint hexokinase 2 in cancer cells to alter the tumor's microenvironment and selectively induce its programmed death without affecting the surrounding normal tissues.

    Vidac Pharma's flagship product, VDA-1275, is currently at the forefront of pharmaceutical innovation. This drug candidate for the treatment of solid tumors has caused a sensation in preclinical studies. When used as a standalone treatment, VDA-1275 has already demonstrated significant efficacy.

    Particularly outstanding are the synergistic effects that occur when VDA-1275 is combined with existing cancer therapies. This combination therapy could set a new standard in oncology.

    Vidac Pharma made a big impression at the Pediatric Brain Tumor Research Meeting in Jerusalem on March 9, 2025, which brought together the elite in tumor research. CEO Herzberg presented the second candidate VDA-1102, which could be formulated in such a way that it could cross the blood-brain barrier in a five-year-old child and thus reach the brain tumor in the child's head, marking a significant milestone that opens up new possibilities for groundbreaking therapies for the treatment of brain diseases.

    Vidac Pharma's shares are consolidating after a rally of over 660% to a high of EUR 1.30 and are currently in the bottoming-out phase in the support zone at EUR 0.50. In their study, analysts at Sphene Capital issued a price target of EUR 4.90, which would mean a price potential of around 870% at the current price level.

    BioNTech – Positive analysts, negative chart

    The results for the fourth quarter and the full year 2024 were met with sell-offs by BioNTech shareholders. Since then, the stock has lost around 13% of its value and again broke the psychological mark of USD 100. Further losses are looming if the price falls below the prominent support area of USD 93. Should this level be breached on a sustained basis, last year's low of USD 76.53 could serve as an intermediate target.

    The end of the COVID-19 pandemic eliminated the largest source of revenue for the Mainz-based biotech company. For fiscal year 2024, revenue totaled EUR 2.75 billion, compared to EUR 3.82 billion in the prior-year period. By contrast, research and development costs grew to EUR 2.3 billion, compared to EUR 1.78 billion in 2023. For fiscal year 2024, the net loss amounted to EUR 665.3 million, compared to a net profit of EUR 930.3 million in the same period last year. The loss per share amounted to EUR 2.77 compared to a profit of EUR 3.83 12 months earlier.

    The Company's beacon of hope for the future is undoubtedly its oncology pipeline, which management says has made significant progress in the past year. Several global Phase 3 clinical trials have been initiated for the antibody candidate BNT327, and new data from the mRNA cancer immunotherapy program have been presented.

    According to Prof. Dr. Ugur Sahin, BioNTech's CEO and co-founder, "2025 will be a year of multiple important data updates from our clinical focus programs. We believe that these candidates, subject to successful development and approval, have the potential to be disruptive and improve on the current standard of care."


    Pharma and agricultural giant Bayer has once again suffered a setback in court and faces the threat of a billion-dollar fine. BioNTech is focusing on developing its oncology pipeline. Vidac Pharma has achieved a milestone.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Stefan Feulner on November 20th, 2026 | 05:55 CET

    Merck KGaA, BioNxt Solutions and Novartis – A billion-dollar market is being reshaped

    • Biotechnology

    Multiple sclerosis has long been a billion-dollar market. But as established drugs come under pressure from expiring patents, new therapeutic approaches are advancing through clinical development. The focus is not just on better active ingredients, but increasingly on easier ways of administering treatments. A German pharmaceutical group is battling generic competition, a small biotech developer is betting on a new drug delivery format, and a Swiss industry giant has reported promising Phase 3 data. This creates significant opportunities for investors, each with a different risk profile.

    Read

    Commented by Armin Schulz on November 18th, 2026 | 05:30 CET

    Pharma Turnaround Stocks Under Review: Evotec, Vidac Pharma and Novo Nordisk – Restructuring, Clinical Trial Results and Outlook

    • Evotec
    • Vidac Pharma
    • Novo Nordisk
    • Drug discovery
    • Biotech
    • Pharma
    • Cancer
    • Oncology
    • Warburg effect
    • Obesity
    • Diabetes
    • Weight-loss pill

    Between November 4 and 9, three pharma and biotech stocks released news that suggests a turning point. At one, the quarterly loss before exceptional items narrowed; at the second, initial data from a placebo-controlled trial are available; and the third has raised its full-year guidance. These are not yet proof of a lasting turnaround, but they are verifiable signs of progress. If this trajectory can be maintained, hope could soon turn into substance. We therefore take a closer look at Evotec, Vidac Pharma and Novo Nordisk to see which has turnaround potential.

    Read

    Commented by Armin Schulz on November 17th, 2026 | 19:35 CET

    Bayer, Cardiol Therapeutics, Novartis – Biotech stocks and pharmaceutical giants in the race for the heart

    • Bayer
    • Cardiol Therapeutics
    • Novartis
    • Heart disease
    • Asundexian
    • Pharma
    • Pericarditis
    • CardiolRx
    • Leqvio

    Created and Published on Behalf of Cardiol Therapeutics

    Cardiology is one of the most exciting fields in the pharmaceutical industry. Four days in Chicago have shown just how much is happening in cardiovascular medicine. From November 6 to 9, pharmaceutical giants and small biotech companies gathered at the American Heart Association Scientific Sessions annual congress with a shared goal: to improve care for patients with cardiovascular disease. The major players bring experience and capital, while smaller companies often contribute fresh ideas. When a company succeeds in securing regulatory approval, investors stand to benefit. This interplay is precisely what makes the market so interesting for investors. We therefore take a closer look at Bayer, Cardiol Therapeutics, and Novartis.

    Read